Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBViNT cell
- Development stage
- Phase 2
- Lead developer
- Eutilex
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EBViNT cell is an autologous adoptive T-cell therapy designed for the treatment of Epstein-Barr virus (EBV)-positive malignancies, particularly relapsed or refractory NK/T-cell lymphoma. The therapy involves isolating and expanding a patient's own CD8+ T cells that are specific to the EBV latent membrane protein 2A (LMP2A) antigen. These cells are then infused back into the patient to target and kill EBV-infected tumor cells. Clinical studies have shown that single infusions of EBViNT are well tolerated and can induce objective antitumor responses in patients who have failed standard treatments[1][2][3][4]. The mechanism of action relies on the cytotoxic activity of LMP2A-specific CD8+ T cells against malignant cells expressing this viral antigen.
- Other names
- Epstein-Barr virus-induced Natural T cellEBV/LMP2A-specific CD8+ T cells
02
Targets
Epstein-Barr virus latent membrane protein 2A peptide-HLA class I complex
Beyond the preview
Go deeper on EBViNT cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBViNT cell.